Revumenib, Revumenib, SNDX-5613, Revumenib, Revumenib, SNDX-5613
SNDX-5613-0700
Phase 2 small_molecule active
Quick answer
Revumenib, Revumenib, SNDX-5613, Revumenib, Revumenib, SNDX-5613 for Relapsed or Refractory Acute Leukemias is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Syndax Pharmaceuticals Inc
- Indication
- Relapsed or Refractory Acute Leukemias
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active